金斯瑞(01548.HK)：传奇生物药物获欧盟批准治疗骨髓瘤

阿斯达克财经04-23

金斯瑞生物科技(01548.HK) 的非全资附属传奇生物(LEGN.US) 公布，欧盟委员会(EC)已批准CARVYKTI (ciltacabtagene autoleucel，cilta-cel)用于治疗复发和难治性多发性骨髓瘤成人患者，该些患者既往接受过至少一种治疗，包括蛋白酶体抑制剂(PI)和免疫调节剂(IMiD)，在最后一次治疗中已证明疾病进展，并且对来那度胺难治。

欧洲批准是基于CARTITUDE-4研究的积极结果，该研究表明，与两种标准治疗方案泊马度胺、硼替佐米和地塞米松(PVd)或达雷妥尤单抗、泊马度胺和地塞米松(DPd)相比，CARVYKTI在既往接受过一到三线治疗的复发和来那度胺难治性多发性骨髓瘤成人患者中，无进展生存期有统计学意义和临床意义。(jl/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-22 16:25。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)

AASTOCKS新闻

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2429184959?lang=zh_CN&edition=full","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20211125141320348_s.jpeg","is_english":false,"pubTime":"2024-04-23 09:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2429184959","market":"sh","top_or_hot":-1,"title":"金斯瑞(01548.HK)：传奇生物药物获欧盟批准治疗骨髓瘤","media":"阿斯达克财经","content":"<html><body><div> <span> <p><a href=\"https://laohu8.com/S/01548\">金斯瑞生物科技</a>(01548.HK)<span> </span>的非全资附属<a href=\"https://laohu8.com/S/LEGN\">传奇生物</a>(LEGN.US)<span> </span><span> </span>公布，欧盟委员会(EC)已批准CARVYKTI (ciltacabtagene autoleucel，cilta-cel)用于治疗复发和难治性多发性骨髓瘤成人患者，该些患者既往接受过至少一种治疗，包括蛋白酶体抑制剂(PI)和免疫调节剂(IMiD)，在最后一次治疗中已证明疾病进展，并且对来那度胺难治。<br/><span></span><br/>欧洲批准是基于CARTITUDE-4研究的积极结果，该研究表明，与两种标准治疗方案泊马度胺、硼替佐米和地塞米松(PVd)或达雷妥尤单抗、泊马度胺和地塞米松(DPd)相比，CARVYKTI在既往接受过一到三线治疗的复发和来那度胺难治性多发性骨髓瘤成人患者中，无进展生存期有统计学意义和临床意义。(jl/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-22 16:25。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)</p><div></div>AASTOCKS新闻 </span> </div></body></html>","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>金斯瑞(01548.HK)：传奇生物药物获欧盟批准治疗骨髓瘤</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n金斯瑞(01548.HK)：传奇生物药物获欧盟批准治疗骨髓瘤\n</h2>\n\n<h4 class=\"meta\">\n\n<p class=\"head\">\n<strong class=\"h-name small\">阿斯达克财经</strong><span class=\"h-time small\">2024-04-23 09:22</span>\n</p>\n\n</h4>\n\n</header>\n<article>\n<html><body><div> <span> <p><a href=\"https://laohu8.com/S/01548\">金斯瑞生物科技</a>(01548.HK)<span> </span>的非全资附属<a href=\"https://laohu8.com/S/LEGN\">传奇生物</a>(LEGN.US)<span> </span><span> </span>公布，欧盟委员会(EC)已批准CARVYKTI (ciltacabtagene autoleucel，cilta-cel)用于治疗复发和难治性多发性骨髓瘤成人患者，该些患者既往接受过至少一种治疗，包括蛋白酶体抑制剂(PI)和免疫调节剂(IMiD)，在最后一次治疗中已证明疾病进展，并且对来那度胺难治。<br/><span></span><br/>欧洲批准是基于CARTITUDE-4研究的积极结果，该研究表明，与两种标准治疗方案泊马度胺、硼替佐米和地塞米松(PVd)或达雷妥尤单抗、泊马度胺和地塞米松(DPd)相比，CARVYKTI在既往接受过一到三线治疗的复发和来那度胺难治性多发性骨髓瘤成人患者中，无进展生存期有统计学意义和临床意义。(jl/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-22 16:25。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)</p><div></div>AASTOCKS新闻 </span> </div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1344142/latest-news/AAFN\">阿斯达克财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1344142/latest-news/AAFN","article_id":"2429184959","we_media_id":null,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20211125141320348_s.jpeg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2429184959","pubTimestamp":1713835320,"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"金斯瑞生物科技的非全资附属传奇生物公布，欧盟委员会已批准CARVYKTI 用于治疗复发和难治性多发性骨髓瘤成人患者，该些患者既往接受过至少一种治疗，包括蛋白酶体抑制剂和免疫调节剂，在最后一次治疗中已证明疾病进展，并且对来那度胺难治。","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","BK4139":"生物科技","BK4588":"碎股","LEGN":"传奇生物","BK1583":"高瓴概念","01548":"金斯瑞生物科技"},"translate_title":"GenScript (01548. HK): Legendary biopharmaceutical approved by EU to treat myeloma","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1,"LEGN":1},"content_text":"金斯瑞生物科技(01548.HK) 的非全资附属传奇生物(LEGN.US)  公布，欧盟委员会(EC)已批准CARVYKTI (ciltacabtagene autoleucel，cilta-cel)用于治疗复发和难治性多发性骨髓瘤成人患者，该些患者既往接受过至少一种治疗，包括蛋白酶体抑制剂(PI)和免疫调节剂(IMiD)，在最后一次治疗中已证明疾病进展，并且对来那度胺难治。欧洲批准是基于CARTITUDE-4研究的积极结果，该研究表明，与两种标准治疗方案泊马度胺、硼替佐米和地塞米松(PVd)或达雷妥尤单抗、泊马度胺和地塞米松(DPd)相比，CARVYKTI在既往接受过一到三线治疗的复发和来那度胺难治性多发性骨髓瘤成人患者中，无进展生存期有统计学意义和临床意义。(jl/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-22 16:25。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)AASTOCKS新闻","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2429184959"}